Chong G L, Thibodeau S N
Molecular Genetics Laboratory, Mayo Clinic, Rochester, MN 55905.
Mayo Clin Proc. 1990 Aug;65(8):1072-6. doi: 10.1016/s0025-6196(12)62719-0.
With the recent identification of the cystic fibrosis gene and the elucidation of one of the major mutations responsible for the disease, it is now possible to screen directly for carriers of this particular mutation at the DNA level. The mutation that accounts for approximately 70% of the affected population in North America has been identified as a deletion of a phenylalanine residue at position 508 of the deduced amino acid sequence of the putative protein. We describe herein a method for screening carriers of this mutation which makes use of the polymerase chain reaction and direct viewing of the mutation by staining with ethidium bromide after electrophoresis of the polymerase chain reaction products on a polyacrylamide gel. This quick and sensitive method avoids the need for hybridization assays and the hazard associated with isotopically labeled probes.
随着最近囊性纤维化基因的鉴定以及导致该疾病的主要突变之一的阐明,现在有可能在DNA水平上直接筛查这种特定突变的携带者。在北美,约70%的受影响人群中出现的突变已被确定为假定蛋白质推导氨基酸序列第508位的苯丙氨酸残基缺失。我们在此描述一种筛查这种突变携带者的方法,该方法利用聚合酶链反应,并在聚丙烯酰胺凝胶上对聚合酶链反应产物进行电泳后,用溴化乙锭染色直接观察突变。这种快速且灵敏的方法避免了杂交检测的需要以及与同位素标记探针相关的风险。